Literature DB >> 12666106

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease.

Anthony H V Schapira1, C Warren Olanow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12666106     DOI： 10.1002/ana.10514

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  16 in total

Review 1.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 2.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 3.  Present and future drug treatment for Parkinson's disease.

Authors:  A H V Schapira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

4.  Religiosity and Risk of Parkinson's Disease in England and the USA.

Authors:  Abidemi I Otaiku
Journal:  J Relig Health       Date:  2022-06-28

5.  Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.

Authors:  Lyle Wiemerslage; Bradley J Schultz; Archan Ganguly; Daewoo Lee
Journal:  J Neurochem       Date:  2013-03-24       Impact factor: 5.372

6.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 7.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

Review 8.  Treatment strategies for Parkinson's disease.

Authors:  Hong Yuan; Zhen-Wen Zhang; Li-Wu Liang; Quan Shen; Xiang-Dang Wang; Su-Mei Ren; Hong-Jie Ma; Shu-Jun Jiao; Ping Liu
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

9.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.

Authors:  Balaram Ghosh; Tamara Antonio; Juan Zhen; Prashant Kharkar; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  Studies on sensitivity of zebrafish as a model organism for Parkinson's disease: Comparison with rat model.

Authors:  Dinesh T Makhija; Aarti G Jagtap
Journal:  J Pharmacol Pharmacother       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.